Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: Role in endothelial inflammation and atheromasia

Journal of Hypertension

Volumn 24, Issue 7, 2006, Pages 1307-1318

  Tucci, Marco ^a   Quatraro, Cosima ^a   Frassanito, Maria Antonia ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Atheromasia; Chemokines; Endothelial inflammation; Hypertension; Monocyte chemoattractant protein 1

Indexed keywords

C REACTIVE PROTEIN; CD133 ANTIGEN; CD31 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMELYSIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DIABETIC NEPHROPATHY; DISEASE DURATION; DNA ISOLATION; DNA POLYMORPHISM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENDER; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; HYPERTENSION; INFLAMMATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

EID: 33745447967     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000234111.31239.c3     Document Type: Article

References (34)

1. Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 2005; 167:1139-1148.
2. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338:436-445.
3. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 2004; 94:1203-1210.
4. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95:858-866.
5. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14:33-37.
6. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension 2003; 41:834-841.
7. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002; 90:1167-1172.
8. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, et al. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002; 22:115-120.
9. Parissis JT, Korovesis S, Giazitzoglou E, Kalivas P, Katritsis D. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. Int J Cardiol 2002; 83:13-21.
10. Haim M, Tanne D, Boyko V, Reshef T, Goldbourt U, Battler A, et al. Monocyte chemoattractant protein-1 and recurrent cardiovascular events in patients with stable coronary heart disease. Clin Cardiol 2005; 28:31-35.
11. Agachan B, Isbir T, Yilmaz H, Akoglu E. Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients. Exp Mol Med 2003; 35:545-549.
12. Ortlepp JR, Vesper K, Mevissen V, Schmitz F, Janssens U, Franke A, et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med 2003; 81:363-367.
13. Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, Richards HB. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004; 50:1842-1849.
14. European Society of Hypertension-European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
15. Makin AJ, Blann AD, Chung NA, Silverman SH, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur Heart J 2004; 25:371-376.
16. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003; 26:2421-2425.
17. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259:344-348.
18. Lijnen HR. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003; 33:275-281.
19. Browatzki M, Larsen D, Pfeiffer CA, Gehrke SG, Schmidt J, Kranzhofer A, et al. Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res 2005; 42:415-423.
20. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with antiinflammatory properties in vivo. Blood 2002; 100:1160-1167.
21. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003; 361:206-210.
22. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J 2002; 66:529-533.
23. Kim WJ, Chereshnev I, Gazdoiu M, Fallon JT, Rollins BJ, Taubman MB. MCP-1 deficiency is associated with reduced intimai hyperplasia after arterial injury. Biochem Biophys Res Commun 2003; 310:936-942.
24. Jiang Y, Beller DI, Frendl G, Graves DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992; 148:2423-2428.
25. Martin T, Cardarelli PM, Parry GC, Felts KA, Cobb RR. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-1. Eur J Immunol 1997; 27:1091-1097.
26. Rose CE Jr, Sung SS, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation 2003; 10:273-288.
27. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599-2610.
28. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108:1917-1923.
29. McDermott DH, Halcox JP, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89:401-407.
30. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001; 158:233-239.
31. Flex A, Gaetani E, Papaleo P, Straface G, Proia AS, Pecorini G, et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 2004; 35:2270-2275.
32. Ping D, Jones PL, Boss JM. TNF regulates the in vivo occupancy of both distal and proximal regulatory regions of the MCP-1/JE gene. Immunity 1996; 4:455-469.
33. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K, et al. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994; 153:2052-2063.
34. Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003; 108:2134-2140.